-
Product Insights
New![]()
Net Present Value Model: AC Immune SA’s ACI-35
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACI-7104 in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ACI-7104 in Parkinson's Disease Drug Details:PD-01 (PD-01A) is under development for the treatment of Parkinson's disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Distal Symmetric Polyneuropathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Distal Symmetric Polyneuropathy Drug Details: Ricolinostat (ACY-1215) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Diabetic Neuropathic Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Diabetic Neuropathic Pain Drug Details: Ricolinostat (ACY-1215) is under development for the treatment...
-
Company Insights
New![]()
Westpac Banking Corporation – Digital Transformation Strategies
Westpac Digital Transformation Strategies Report Overview Westpac uses cloud technologies as a part of its digital transformation strategies. The annual ICT spending of Westpac was estimated at $1.7 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. Westpac Banking (Westpac) is a provider of personal, private, business, and corporate banking solutions. Its portfolio of products consists of accounts, cards, life and non-life insurance, personal and business loans, mortgages, overdraft...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Citarinostat in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Citarinostat in Melanoma Drug Details: Citarinostat (ACY-241) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Citarinostat in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Citarinostat in Relapsed Multiple Myeloma Drug Details: Citarinostat (ACY-241) is under development for the treatment...
-
Product Insights
New![]()
Net Present Value Model: Cerevel Therapeutics Holdings Inc’s Tavapadon
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Citarinostat in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Citarinostat in Non-Small Cell Lung Cancer Drug Details: Citarinostat (ACY-241) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Citarinostat in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Citarinostat in Refractory Multiple Myeloma Drug Details: Citarinostat (ACY-241) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Citarinostat in Multiple Myeloma (Kahler Disease)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Citarinostat in Multiple Myeloma (Kahler Disease) Drug Details: Citarinostat (ACY-241) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Chronic Lymphocytic Leukemia (CLL) Drug Details: Ricolinostat (ACY-1215) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Chemotherapy Induced Peripheral Neuropathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Chemotherapy Induced Peripheral Neuropathy Drug Details: Ricolinostat (ACY-1215) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Charcot-Marie-Tooth Disease Type II
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Charcot-Marie-Tooth Disease Type II Drug Details: Ricolinostat (ACY-1215) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Relapsed Multiple Myeloma Drug Details: Ricolinostat (ACY-1215) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Refractory Multiple Myeloma Drug Details: Ricolinostat (ACY-1215) is under development for the treatment...
-
Thematic Analysis
![]()
Ecommerce – Thematic Intelligence
Ecommerce Report Overview The e-commerce market was worth $5.9 trillion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of more than 9% between 2022 and 2027 primarily driven by improved technology and delivery services and wider internet adoption. The E-commerce thematic report provides an overview of the e-commerce theme. It identifies the key trends impacting the growth of the sector over the next 12 to 24 months. It includes a comprehensive industry analysis, outlining...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vanadis-03 in Acute Renal Failure (ARF) (Acute Kidney Injury)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Vanadis-03 in Acute Renal Failure (ARF) (Acute Kidney Injury)Drug Details:Vanadis-03 is under development for the treatment...
-
Product Insights
![]()
Acis Group/ GLLEP/ Homes England – Bowling Green Road Residential Community – Lincolnshire
Equip yourself with the essential tools needed to make informed and profitable decisions with our Acis Group/ GLLEP/ Homes England - Bowling Green Road Residential Community - Lincolnshire report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details: KITE-222 is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.